Related Experiment Video
Updated: Apr 16, 2026
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
Published on: September 6, 2024
Successful topical rapamycin treatment for facial angiofibromata in two children
Emma V Pynn1, Jemma Collins1, Prasad R Y Hunasehally2
1Welsh Institute of Dermatology, University Hospital of Wales, Cardiff, Wales, UK.
Abstract:
Topical sirolimus, or rapamycin, is known to inhibit tumorigenesis in tuberous sclerosis. We report two cases of successful treatment of children with facial angiofibromata and summarize the encouraging evidence of the effectiveness of this therapy in the literature.
Insights
Topical sirolimus (rapamycin) effectively treats facial angiofibromas in children with tuberous sclerosis. This therapy shows promising results for managing these common skin lesions.
Area of Science:
- Dermatology
- Oncology
- Genetics
Background:
- Tuberous sclerosis complex (TSC) is a genetic disorder.
- Facial angiofibromas are common manifestations of TSC.
- Sirolimus (rapamycin) is an mTOR inhibitor with known anti-tumorigenic properties.
Observation:
- Two pediatric cases of facial angiofibromas associated with TSC were treated.
- Topical sirolimus was administered as the therapeutic intervention.
- Treatment outcomes were monitored for efficacy and safety.
Findings:
- Both reported cases demonstrated successful treatment of facial angiofibromas with topical sirolimus.
- The therapy was well-tolerated by the pediatric patients.
- Literature review supports the effectiveness of sirolimus for TSC-related lesions.
Implications:
- Topical sirolimus represents a viable and effective treatment option for facial angiofibromas in children with TSC.
- This approach may improve cosmetic outcomes and quality of life for affected individuals.
- Further research into mTOR inhibitors for TSC management is warranted.
